Key facts
- It has raised $99.7M; the latest was Early Stage VC ($60.0M) in Nov 2025.
- Notable investors include Samsung Venture Investment, Lapam Capital, Xiamen C&D Corporation, Hankang Capital, Shanghai Guofang Private Equity Fund Management Company — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Phrontline Biopharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Phrontline Biopharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Phrontline Biopharma
Developer of advanced biopharmaceutical products intended for complex cancer pathways through innovative antibody-drug conjugate technology. The company offers a proprietary bispecific ADC platform with dual-payload capabilities, enabling oncology researchers and clinicians to enhance therapeutic efficacy for patients with aggressive solid tumors across diverse clinical settings.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2022
- Employees
- 35
- Website
- phrontlinebio.com/
- Ownership
- Privately Held (backing)
Phrontline Biopharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Phrontline Biopharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Phrontline Biopharma in its N-PORT filings yet. We sweep new filings monthly.